Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.C2N Diagnostics has launched its new SILK-Aß, a commercial assay and research service for the measurement of neurally-derived biomolecules in vivo.
Subscribe to our email newsletter
The SILK-Aß assay refers to the use of stable isotope labeling and tandem mass spectrometry for the measurement of the kinetics, or metabolism, of amyloid-beta. Amyloid-beta is a small peptide implicated as a key mediator of Alzheimer’s disease.
Joel Braunstein, managing member of C2N Diagnostics, said: “With the industry availability of this assay, for the first time, it is now possible for pharmaceutical and biotechnology companies to readily evaluate the impact of their development-stage compounds on the production and clearance rates of amyloid-beta.
The sensitivity of the assay intends to enable clinical researchers the ability to discriminate active from inactive drugs with a remarkably small number of patients.”